Benchmarking the centralized urgent plasma exchange service for patients admitted with a diagnosis of suspected acquired thrombotic thrombocytopenic purpura at a large healthcare system
- 25 June 2021
- journal article
- research article
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 36 (5) , 678-686
Abstract
Background: Consensus guidelines recommend that therapeutic plasma exchange (TPE) should be started within 4 to 8 hours after the diagnosis of suspected acquired thrombotic thrombocytopenic purpura (aTTP). This study aimed to audit the steps from diagnosis to initiation of plasma exchange at a centralized apheresis service.Methods: A retrospective review of the electronic medical record and laboratory information systems from January 1, 2014 to August 31, 2017 was conducted to identify all patients with suspected aTTP undergoing TPE. Demographics, comorbidities, pertinent laboratory tests, and temporal TPE procedural data were collected.Results: The median (5th‐95th percentile) time from request to initiation of TPE was 5.4 (3.2‐10.6) hours. TPE was initiated within 8 hours in 94 of the 108 patients (87.0%). The median (5th‐95th percentile) time from request to central venous access was 2.5 (0.5‐6.9) hours and from request to plasma product issuance from the blood bank was 3.4 (1.6‐8.1) hours. aTTP patients in whom TPE was initiated greater than 6 hours from request did not have worse outcomes compared to those with TPE initiation within 6 hours: in‐hospital mortality (2/14 [14.3%] vs 2/21 [9.5%], P = 0.66), median length of stay (9.0 [4.7‐44.1] vs 8.3 [3.9‐27.0] days, P = 0.76), and median number of days to durable platelet count recovery (4.5 [2.0‐9.0] vs 4.0 [2.0‐18.0] days, P = 0.66).Conclusions: The 4 to 8‐hour target window from TPE request to initiation appears feasible for a centralized apheresis program servicing a large healthcare system.Keywords
This publication has 13 references indexed in Scilit:
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special IssueJournal of Clinical Apheresis, 2019
- Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic PurpuraNew England Journal of Medicine, 2019
- Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpuraJournal of Thrombosis and Haemostasis, 2017
- Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort studyThe Lancet Haematology, 2017
- Caplacizumab for Acquired Thrombotic Thrombocytopenic PurpuraNew England Journal of Medicine, 2016
- Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathiesBritish Journal of Haematology, 2012
- High-Dose Plasma Infusion versus Plasma Exchange as Early Treatment of Thrombotic Thrombocytopenic Purpura/Hemolytic-Uremic SyndromeMedicine, 2003
- Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchangeAnnals of Hematology, 1995
- Comparison of Plasma Exchange with Plasma Infusion in the Treatment of Thrombotic Thrombocytopenic PurpuraNew England Journal of Medicine, 1991
- THROMBOTIC THROMBOCYTOPENIC PURPURAMedicine, 1966